Cat. No.: HY-N1986

Cucurbitacin D

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Cucurbitacin D is the active ingredient in Trichosanthes kirilowii and can disrupt the interaction between Hsp90 and two co-chaperones, Cdc37 and p23. Cucurbitacin D is an inflammasome activator. Cucurbitacin D induces cell cycle arrest and cell apoptosis, exhibiting anti-tumor and anti-inflammatory effects.

For research use only. We do not sell to patients.

Purity: 99.93%
CAS No.: 3877-86-9
Formula: C₃₀H₄₄O₇
Molecular Weight:516.67

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Cucurbitacin D Chemical Structure

CAS No.: 3877-86-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

HSP90

All HSP Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
Bel-7402	IC₅₀	1.41 μM Compound: 143	Cytotoxicity against human Bel7402 cells assessed as growth inhibition Cytotoxicity against human Bel7402 cells assessed as growth inhibition	[PMID: 25599949]
Cancer cell lines	IC₅₀	<0.4 μM Compound: Cucurbitacin D	Growth inhibition of human breast cancer cells Growth inhibition of human breast cancer cells	[PMID: 15332833]
Cancer cell lines	IC₅₀	<0.4 μM Compound: Cucurbitacin D	Growth inhibition of human CNS cancer cells Growth inhibition of human CNS cancer cells	[PMID: 15332833]
Cancer cell lines	IC₅₀	<0.4 μM Compound: Cucurbitacin D	Growth inhibition of human colon cancer cells Growth inhibition of human colon cancer cells	[PMID: 15332833]
Cancer cell lines	IC₅₀	<0.4 μM Compound: Cucurbitacin D	Growth inhibition of human lung cancer cells Growth inhibition of human lung cancer cells	[PMID: 15332833]
HeLa	IC₅₀	0.7 μM Compound: 3	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 21459003]
HepG2	EC₅₀	9 μM Compound: 3	Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay Hepatoprotective activity in human HepG2 cells assessed as inhibition of CCl4-induced toxicity after 24 hrs by MTT assay	[PMID: 21459003]
HepG2	IC₅₀	77.33 μM Compound: 3	Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs assessed as inhibition of cell viability by MTT assay	[PMID: 21459003]
HSC-T6	EC₅₀	0.07 μM Compound: 3	Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay Antiproliferative activity against serum-stimulated rat HSC-T6 cells after 24 hrs by MTT assay	[PMID: 21459003]
HSC-T6	IC₅₀	26 μM Compound: 3	Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay Cytotoxicity against rat HSC-T6 cell after 24 hrs by MTT assay	[PMID: 21459003]
HT-29	IC₅₀	>10 μM Compound: 9	Cytotoxicity against human HT-29 cells after 3 days by mitochondrial transmembrane potential assay Cytotoxicity against human HT-29 cells after 3 days by mitochondrial transmembrane potential assay	[PMID: 22239601]
HT-29	IC₅₀	0.12 μM Compound: 9	Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 3 days by sulforhodamine B assay	[PMID: 22239601]
JY	IC₅₀	1.36 μM Compound: 4	Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay Inhibition of LFA1 expressed in human JY cells interaction with ICAM1-IG expressed in human HeLa cell monolayer after 45 mins by cell adhesion assay	[PMID: 7852999]
MCF7	GI₅₀	0.02 μM Compound: 2	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 14640532]
MCF7	IC₅₀	0.598 μM Compound: 4	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay	[PMID: 25756299]
NCI-H460	GI₅₀	0.013 μM Compound: 2	Cytotoxicity against human H460 cells Cytotoxicity against human H460 cells	[PMID: 14640532]
NCI-H460	IC₅₀	0.12 μg/mL Compound: 5	Antiproliferative activity against human NCI-H460 cells after 72 hrs Antiproliferative activity against human NCI-H460 cells after 72 hrs	[PMID: 17190463]
SF-268	GI₅₀	0.021 μM Compound: 2	Cytotoxicity against human SF268 cells Cytotoxicity against human SF268 cells	[PMID: 14640532]
SK-MEL-28	IC₅₀	1.22 μM Compound: 143	Cytotoxicity against human SK-MEL-28 cells assessed as growth inhibition Cytotoxicity against human SK-MEL-28 cells assessed as growth inhibition	[PMID: 25599949]

In Vitro

Cucurbitacin D (0.5 μg/mL, 24 h) combined with doxorubicin can induce apoptosis in MCF7/ADR cells and cause G2/M cell cycle arrest^[1].
Cucurbitacin D (0.125-16 μg/mL, 24-72 h) significantly inhibits the growth of MCF7 and MCF7/ADR cells in a dose- and time-dependent manner^[1].
Cucurbitacin D (0.5-2 μg/mL, 24 h) inhibits STAT3 signaling in MCF7/ADR cells and suppresses the NF-κB signaling pathway^[1].
Cucurbitacin D enhances the production of IL-1β in LPS (HY-D1056) induced THP-1, PECs, BMDMs, and RAW264 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

MCF7/ADR induced by doxorubicin
Concentration:

0.5, 2 μg/mL
Incubation Time:

24 h
Result:

Reduced p-STAT3 levels, increased the expression of IκB and NF-κB in the cytoplasm, and reduced the expression of pNF-κB in the nucleus.

Cell Viability Assay^[1]

Cell Line:

MCF7, MCF7/ADR
Concentration:

0.125, 0.5, 2, 4, 8, 16 μg/mL
Incubation Time:

24, 48, 72 h
Result:

Inhibited cell proliferation.

Apoptosis Analysis^[1]

Cell Line:

MCF7/ADR
Concentration:

0.5 μg/mL
Incubation Time:

24 h
Result:

Increased apoptosis by 114%.

Cell Cycle Analysis^[1]

Cell Line:

MCF7/ADR
Concentration:

0.5 μg/mL
Incubation Time:

24 h
Result:

Induced G2/M cell cycle arrest.

In Vivo

Cucurbitacin D (1 mg/kg, intratumoral injection, three times a week for four weeks) inhibits tumor proliferation in mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Xenograft cervical cancer cell model in nude mice^[3]
Dosage:

1 mg/kg; three times a week; four weeks
Administration:

Intratumoral injection
Result:

Reduced tumor volume and weight, and the expression of pAKT and pSTAT3 proteins was significantly reduced.

Chemical Information

CAS No. 3877-86-9
Appearance Solid
Molecular Weight 516.67
Formula C₃₀H₄₄O₇
Color White to off-white
SMILES

C[C@@]([C@@](CC=C(C(C)1C)[C@@]2([H])C[C@H](O)C1=O)([H])[C@@]2(C)C3=O)(C[C@@H](O)[C@]4([H])[C@@](C)(O)C(/C=C/C(C)(O)C)=O)[C@@]4(C3)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (1)

All

Sort by:

Journal Impact Factor

Biology (Basel)

Transcriptomic and Metabolomic Profiling Reveals the Antiproliferative Mechanism of Goose Serum and Plasma in SW1990 Cells. [Abstract]

2026 May 15;15(10):788. PMID: 42187750

Solvent & Solubility

In Vitro:

DMSO : 110 mg/mL (212.90 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9355 mL

9.6774 mL

19.3547 mL

5 mM

0.3871 mL

1.9355 mL

3.8709 mL

10 mM

0.1935 mL

0.9677 mL

1.9355 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.75 mg/mL (5.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.75 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.75 mg/mL (5.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Jin Mo Ku, et al. Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells. Mol Cell Biochem. 2015 Nov;409(1-2):33-43. [Content Brief]

[2]. Yuan Song, et al. Cucurbitacin D is a new inflammasome activator in macrophages. Int Immunopharmacol. 2013 Dec;17(4):1044-50. [Content Brief]

[3]. Mohammed Sikander, et al. Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer. Sci Rep. 2016 Nov 8:6:36594. [Content Brief]

[4]. Hall JA, et al. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery. J Nat Prod. 2015 Apr 24;78(4):873-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9355 mL	9.6774 mL	19.3547 mL	48.3868 mL
	5 mM	0.3871 mL	1.9355 mL	3.8709 mL	9.6774 mL
	10 mM	0.1935 mL	0.9677 mL	1.9355 mL	4.8387 mL
	15 mM	0.1290 mL	0.6452 mL	1.2903 mL	3.2258 mL
	20 mM	0.0968 mL	0.4839 mL	0.9677 mL	2.4193 mL
	25 mM	0.0774 mL	0.3871 mL	0.7742 mL	1.9355 mL
	30 mM	0.0645 mL	0.3226 mL	0.6452 mL	1.6129 mL
	40 mM	0.0484 mL	0.2419 mL	0.4839 mL	1.2097 mL
	50 mM	0.0387 mL	0.1935 mL	0.3871 mL	0.9677 mL
	60 mM	0.0323 mL	0.1613 mL	0.3226 mL	0.8064 mL
	80 mM	0.0242 mL	0.1210 mL	0.2419 mL	0.6048 mL
	100 mM	0.0194 mL	0.0968 mL	0.1935 mL	0.4839 mL

Keywords

Cucurbitacin D

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Cucurbitacin D

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Lipid Compound Library

Endoplasmic Reticulum Stress Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Extracellular Vesicles (EVs) Compound Library

Inflammasomes related Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Tibetan Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cucurbitacin D

All HSP Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Cucurbitacin D Related Classifications

HY-N1986 Related Classifications